SCHEMBL22092154

SCHEMBL22092154

CC(=NOCc1ccc(Br)cc1)c1ccc(OCC(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.56
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
S1PR1 P21453 5/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 1/20 0.49
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
MAPT P10636 1/20 0.46
HRH3 Q9Y5N1 1/20 0.44
PPARD Q03181 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22092153 1.00 MAOB (0.56) MAOBRXRARXRBS1PR1NPC1
SCHEMBL22092365 0.89 S1PR1 (0.62) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL22092363 0.89 S1PR1 (0.62) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL29451166 0.88 MAOB (0.53) MAOBRXRARXRBS1PR1NPC1
SCHEMBL22092155 0.86 MAOB (0.59) MAOBNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL22092156 0.86 MAOB (0.59) MAOBNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL16914904 0.84 S1PR1 (0.61) MAOBS1PR1SMN1; SMN2PPARGPPARA
SCHEMBL22092143 0.84 NPC1 (0.51) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL22092142 0.84 NPC1 (0.51) S1PR1NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL17601795 0.84 S1PR1 (0.61) MAOBS1PR1SMN1; SMN2PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220062215-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-03-03 US claimed
WO-2020122380-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT 고려대학교 산학협력단 2020-06-18 WO claimed
US-12246002-B2 Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-03-11 US disclosed
US-20220062215-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2022-03-03 US disclosed
WO-2020122380-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT 고려대학교 산학협력단 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220062215-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT PER2, CRY1, CRY2 MAOB 50/4885RXRA 1429/4885RXRB 328/4885
US-12246002-B2 Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient PER2, CRY1, CRY2 MAOB 50/4885RXRA 1429/4885RXRB 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.